These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 17255299)

  • 1. Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
    McDermott DF
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):716s-720s. PubMed ID: 17255299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
    McDermott DF; Regan MM; Atkins MB
    Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
    McDermott DF; Atkins MB
    Semin Oncol; 2006 Oct; 33(5):583-7. PubMed ID: 17045087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of metastatic renal cell carcinoma.
    McDermott DF; Atkins MB
    Cancer J; 2008; 14(5):320-4. PubMed ID: 18836337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.
    Atkins MB; Regan M; McDermott D
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6342S-6S. PubMed ID: 15448028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of IL-2 and other cytokines in renal cancer.
    McDermott DF; Atkins MB
    Expert Opin Biol Ther; 2004 Apr; 4(4):455-68. PubMed ID: 15102596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of metastatic renal cell carcinoma.
    McDermott DF
    Cancer; 2009 May; 115(10 Suppl):2298-305. PubMed ID: 19402060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for renal cell carcinoma.
    Rosenblatt J; McDermott DF
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma.
    Clement JM; McDermott DF
    Clin Genitourin Cancer; 2009 Aug; 7(2):E7-9. PubMed ID: 19692326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The application of high-dose interleukin-2 for metastatic renal cell carcinoma.
    McDermott DF
    Med Oncol; 2009; 26 Suppl 1():13-7. PubMed ID: 19148594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine therapy for metastatic renal cell carcinoma.
    Bukowski RM
    Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.
    Ridolfi L; de Rosa F; Ridolfi R; Gentili G; Valmorri L; Scarpi E; Parisi E; Romeo A; Guidoboni M
    J Transl Med; 2014 Sep; 12():262. PubMed ID: 25245327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.
    Allard CB; Gelpi-Hammerschmidt F; Harshman LC; Choueiri TK; Faiena I; Modi P; Chung BI; Tinay I; Singer EA; Chang SL
    Urol Oncol; 2015 Nov; 33(11):496.e11-6. PubMed ID: 26210683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting response to interleukin-2 therapy among patients with renal cell carcinoma.
    Leppert JT; Lam JS; Belldegrun AS
    J Immunother; 2005; 28(5):427-9. PubMed ID: 16113598
    [No Abstract]   [Full Text] [Related]  

  • 17. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
    Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
    Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytokine therapy for metastatic renal cell carcinoma].
    Eto M; Naito S
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma.
    Mickisch GH
    Eur Urol; 2003 Jun; 43(6):670-9. PubMed ID: 12767369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.